4-(丙烯酰氨基)苯酰胺 | 17090-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(丙烯酰氨基)苯酰胺
• 中文别名: 4-(丙烯酰氨基)苯甲酰胺
• 英文名称: 4-Acryloylamino-benzamid
• 英文别名: 4-(Acryloylamino)benzamide；4-(prop-2-enoylamino)benzamide
• CAS: 17090-31-2
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: XNZARJWTVPTCFX-UHFFFAOYSA-N

物化性质

• 沸点：
  444.7±37.0 °C(Predicted)
• 密度：
  1.244±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-(2-吡啶基)哌嗪 、 4-(丙烯酰氨基)苯酰胺 以 二甲基亚砜 为溶剂， 反应 16.0h， 以72%的产率得到4-[3-(4-Pyridin-2-yl-piperazin-1-yl)-propionylamino]-benzamide
  参考文献：
  名称：

  1-2-(Pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic and mast cell stabilizing activities

  摘要：

  New 1-(2-pyridinyl)piperazine derivatives were synthesized and tested as inhibitors of the reaginic passive cutaneous anaphylaxis in the rat (PCA), of the histamine-induced bronchospasm in the guinea pig, and of the rat mesenteric mast cell degranulation induced by compound 48/80. On the basis of test results, a series of N-(substituted phenyl)-omega-[4-(2-pyridinyl)-1-piperazinyl]alkanamides was prepared. The nature of substituents at the anilide ring strongly influenced mast cell stabilizing activity, whereas it was less determining in the case of the other two tests. No clear correlation between the most common physicochemical parameters (pi, sigma, Vw volume) of substituents and activity could be detected. With regard to the position of substituents at the anilide ring, the rank order of potency, in the PCA and bronchoconstriction tests, was para greater than meta greater than ortho. Introduction of substituents in the 1-(2-pyridinyl)piperazinyl moiety of the N-(substituted phenyl)propanamide derivatives hardly affected activity, or the effect was deleterious. Some of the new compounds exhibited a simultaneous remarkable activity in all the three assays employed.

  DOI：

  10.1021/jm00384a002
• 作为产物：
  描述：

  对氨基苯甲酰胺 、 三乙胺 、 丙烯酰氯 、 在 ice 、 水 、 甲醇 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以to give 4-acrylamidobenzamide at a yield of 60%的产率得到4-(丙烯酰氨基)苯酰胺
  参考文献：
  名称：

  Temperature-responsive polymer compound and process for producing the same

  摘要：

  提供了一种温度敏感的聚合物和聚合物材料，其在侧链中的一个或多个位置具有酯键和/或酸酰胺键，并且可以通过改变侧链任意控制。同时还提供了其生产过程和使用方法。

  公开号：

  US20050224415A1

文献信息

• Antihypertensive N-piperazinylalkanoylanilides
  申请人：RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY

  公开号：EP0120558A1

  公开（公告）日：1984-10-03

  N-piperazinylalkanoylanilides of formula wherein is O, 1 or2, each of Rand R, is H or alkyl, and each of R2, R3 and R4 is H, halogen, alkyl, hydroxy-alkyl, alkoxy, aralkoxy, alkylthio, aralkylthio, alkylsulphonyl, alkylsulphenyl, NO2, NH2, alkylamino, acylamino, ureido, alkylureido, alkylsulphonylamino, CF3, acyl, CN, COOH, alkoxycarbonyl, NH2CO, SO3H, guanidinosulphonyl, NH2COO, OH, acyloxy, alkylsulphonyloxy, alkylenedioxy or SO2NR5R6 wherein each of R5 and R6 is H, alkyl, aryl or acyl, and their pharmaceutically acceptable acid addition salts, are antihypertensive agents. They may be prepared by condensing 1-(2-methoxyphenyl)- -piperazine with an alkanoylanilide of formula

  式中的 N-哌嗪基烷酰基苯胺 其中 O、1 或 2，Rand R、中的每一个是 H 或烷基，R2、R3 和 R4 中的每一个是 H、卤素、烷基、羟基烷基、烷氧基、芳基氧基、烷硫基、芳基硫基、烷基磺酰基、烷基磺酰基、NO2、NH2、烷基氨基、酰氨基、脲基、烷基脲基、烷基磺酰基氨基、CF3、酰基、CN、COOH、烷氧羰基、NH2CO、SO3H、胍基磺酰基、NH2COO、OH、酰氧基、烷基磺酰氧基、烷二氧基或 SO2NR5R6（其中 R5 和 R6 各为 H、烷基、芳基或酰基）及其药学上可接受的酸加成盐是降压药。 它们可通过将 1-(2-甲氧基苯基)-哌嗪与式中的烷酰苯胺缩合而制备。
• Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10906889B2

  公开（公告）日：2021-02-02

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了新颖的式(I)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同分异构体、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及本发明化合物或组合物的方法和试剂盒，用于治疗或预防受试者的增殖性疾病（如癌症（如白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤文氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可抑制激酶的异常活性，如细胞周期蛋白依赖性激酶（CDK）（如细胞周期蛋白依赖性激酶7（CDK7）、细胞周期蛋白依赖性激酶12（CDK12）或细胞周期蛋白依赖性激酶13（CDK13）），从而诱导细胞凋亡和/或抑制受试者的转录。
• CATTO A.; MOTTA G.; TAJANA A.; CAZZULANI P.; NARDI D.; LEONARDI A., J. MED. CHEM., 30,(1987) N 1, 13-19
  作者：CATTO A.、 MOTTA G.、 TAJANA A.、 CAZZULANI P.、 NARDI D.、 LEONARDI A.

  DOI：——

  日期：——
• TEMPERATURE-RESPONSIVE POLYMER COMPOUND AND PROCESS FOR PRODUCING THE SAME
  申请人：Amersham Pharmacia Biotech K.K.

  公开号：EP1153049A1

  公开（公告）日：2001-11-14
• POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3057956B1

  公开（公告）日：2021-05-05